Dexcom Inc
NASDAQ:DXCM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dexcom Inc
Depreciation & Amortization
Dexcom Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Dexcom Inc
NASDAQ:DXCM
|
Depreciation & Amortization
$251.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
30%
|
CAGR 10-Years
37%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Depreciation & Amortization
$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Depreciation & Amortization
$156.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Depreciation & Amortization
$1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Depreciation & Amortization
$3.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Depreciation & Amortization
$677.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Dexcom Inc
Glance View
Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.
See Also
What is Dexcom Inc's Depreciation & Amortization?
Depreciation & Amortization
251.8m
USD
Based on the financial report for Dec 31, 2025, Dexcom Inc's Depreciation & Amortization amounts to 251.8m USD.
What is Dexcom Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
37%
Over the last year, the Depreciation & Amortization growth was 16%. The average annual Depreciation & Amortization growth rates for Dexcom Inc have been 17% over the past three years , 30% over the past five years , and 37% over the past ten years .